Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 23Observational 6Expanded_access 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1Carcinoma 1Adenocarcinoma 1

Interventions

Afatinib 3ceritinib 2Gefitinib 2zipalertinib 1zenocutuzumab 1ulixertinib 1trilaciclib 1telisotuzumab vedotin 1tazemetostat 1taletrectinib 1sotorasib 1selpercatinib 1rovalpituzumab tesirine 1rociletinib 1pralsetinib 1pegilodecakin 1patritumab deruxtecan 1osimertinib 1mobocertinib 1lorlatinib 1lazertinib 1epigallocatechin gallate 1ensartinib 1dabrafenib 1cemiplimab 1capmatinib 1brigatinib 1belagenpumatucel L 1balstilimab 1amivantamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × brigatinib × Thoracic × Clear all
NCT02784158 2018-02-06

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

Takeda

No longer available
Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡